These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 29909581

  • 1. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
    Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T.
    Med Oncol; 2018 Jun 16; 35(7):108. PubMed ID: 29909581
    [Abstract] [Full Text] [Related]

  • 2. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Yokomura K, Koshimizu N, Sato M, Toyoshima M, Shirai T, Masuda M, Yamada T, Imokawa S, Suda T.
    Eur J Cancer; 2016 May 16; 58():30-7. PubMed ID: 26922170
    [Abstract] [Full Text] [Related]

  • 3. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Suda T, Chida K.
    Cancer Chemother Pharmacol; 2013 Aug 16; 72(2):445-52. PubMed ID: 23807323
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Koba T, Minami S, Nishijima-Futami Y, Masuhiro K, Kimura H, Futami S, Yaga M, Mori M, Kagawa H, Uenami T, Kohmo S, Otsuka T, Yamamoto S, Komuta K, Kijima T.
    Cancer Chemother Pharmacol; 2018 Jul 16; 82(1):111-117. PubMed ID: 29728800
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Fukushima T, Wakatsuki Y, Kobayashi T, Sonehara K, Tateishi K, Yamamoto M, Masubuchi T, Yoshiike F, Hirai K, Hachiya T, Koizumi T.
    Cancer Chemother Pharmacol; 2018 Jun 16; 81(6):1043-1050. PubMed ID: 29644460
    [Abstract] [Full Text] [Related]

  • 6. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    Tsutani Y, Miyata Y, Masuda T, Fujitaka K, Doi M, Awaya Y, Kuyama S, Kitaguchi S, Ueda K, Hattori N, Okada M.
    BMC Cancer; 2018 Dec 10; 18(1):1231. PubMed ID: 30526545
    [Abstract] [Full Text] [Related]

  • 7. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
    Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R, CLICaP.
    PLoS One; 2016 Dec 10; 11(5):e0154293. PubMed ID: 27191954
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
    Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M, Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H.
    BMC Cancer; 2018 Mar 02; 18(1):241. PubMed ID: 29499653
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
    Kaira K, Imai H, Souma R, Sakurai R, Miura Y, Sunaga N, Kasahara N, Tsukagoshi Y, Koga Y, Kitahara S, Kotake M, Minato K, Naruse I, Fukushima Y, Hisada T, Ishizuka T.
    Anticancer Res; 2019 May 02; 39(5):2483-2491. PubMed ID: 31092443
    [Abstract] [Full Text] [Related]

  • 12. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L, Sørensen JB.
    Anticancer Res; 2015 Nov 02; 35(11):6255-9. PubMed ID: 26504059
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M, Hokkaido Lung Cancer Clinical Study Group.
    Int J Clin Oncol; 2018 Dec 02; 23(6):1060-1069. PubMed ID: 30027464
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A, Kubota K, Hosomi Y, Okuma Y, Minato K, Fujimoto S, Okamoto H, Satouchi M, Isobe H, Aono H, Takiguchi Y, Gemma A, Tokyo Cooperative Oncology Group.
    Jpn J Clin Oncol; 2019 Aug 01; 49(8):749-754. PubMed ID: 31070750
    [Abstract] [Full Text] [Related]

  • 16. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P, Corral J, San Antonio B, Chouaki N, John W, Zimmermann A, Visseren-Grul C, Gridelli C.
    Clin Lung Cancer; 2014 Nov 01; 15(6):418-25. PubMed ID: 25104617
    [Abstract] [Full Text] [Related]

  • 17. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.
    Cancer Chemother Pharmacol; 2013 Nov 01; 72(5):1103-10. PubMed ID: 24057043
    [Abstract] [Full Text] [Related]

  • 18. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
    Tamiya M, Tamiya A, Shiroyama T, Takeoka S, Naito Y, Omachi N, Kimura Y, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T.
    Invest New Drugs; 2018 Aug 01; 36(4):608-614. PubMed ID: 29101518
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.
    J Clin Oncol; 2013 Aug 20; 31(24):3004-11. PubMed ID: 23835708
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
    Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V.
    Cancer Chemother Pharmacol; 2013 Mar 20; 71(3):605-12. PubMed ID: 23338050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.